Friday, January 27th | 5 Shevat 5783

Subscribe
April 27, 2020 9:10 am
0

Israeli Developers of Corona Vaccine to Initiate Human Clinical Trials in Summer

× [contact-form-7 404 "Not Found"]

avatar by JNS.org

An Israeli police officer helps a Health Ministry inspector put on protective gear before they go up to the apartment of a person in self-quarantine as a precaution against the spread of the coronavirus, in Hadera, Israel, March 16, 2020. Photo: Reuters / Ronen Zvulun.

JNS.org – An Israeli company working on a COVID-19 vaccine that will begin human trials this summer, a senior company official said on Wednesday.

MigVax, an affiliate of the Migal Galilee Research Institute, will conduct safety and efficacy assessment in rodents starting next month.

Phase 1 of clinical trials in humans will start during the summer and last six to nine months, said Professor Itamar Shalit, senior MigVax researcher and director, during a webinar hosted by the Israeli crowdfunding investment platform OurCrowd, as reported by The Jerusalem Post.

The startup is working to adapt a vaccine against infectious bronchitis virus (IBV)—a coronavirus strain causing bronchial disease in poultry—for human use.

Related coverage

January 27, 2023 1:46 pm

Terror Attack in East Jerusalem Leaves 8 Dead, Assailant ‘Neutralized’

i24 News -  A terror attack on Friday left seven people dead and three wounded in the ultra-Orthodox neighborhood Neve Ya'akov...

According to The Jerusalem Post, “MigVax researchers aim to adapt the vaccine for the avian coronavirus into a new oral sub-unit human vaccine against COVID-19, based on their great genetic similarity and identical infection mechanism. Except for some required genetic adjustments, researchers say the same vaccination concepts should apply in humans.”

MigVax said it will be possible to quickly and inexpensively manufacture millions of doses of the potential vaccine, which is made using bacterial fermentation. Since it does not include the virus itself, researchers said it will also be safe to use on immune-compromised patients and has fewer risks of side effects.

On Wednesday, MigVax announced that it had secured a $12 million investment led by OurCrowd to help accelerate efforts to develop the vaccine.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.